Diarrhea
Recent clinical, regulatory, research and industry developments relating to this disease.
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Immune evasion strategies of bovine viral diarrhea virus.
Symptoms, complications and management of long COVID: a review.
Bacillus cereus food intoxication and toxicoinfection.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
- Active recent publication activity.
- 6 industry developments reported.
- Q4 2026Treatment of Bile Acid Diarrhoea With Atorvastatin (BASTA): A Randomised, Double-Blind, Placebo-Controlled, Crossover, Investigator-Initiated Trial
- Q2 2027A Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT Alone
Research HighlightsViewHide
- 2025-12-02Association between climatic conditions and infectious diseases: implications for Central Ethiopia region.Lambebo IH · 2025
Clinical MilestonesView all 10Hide
- 2026-04-14Next Generation ORS: Randomized Controlled Trial Comparing ORS With Calcium vs Standard ORS in Reducing Severity With Acute Watery Diarrhea in AdultsResults posted
- 2026-02-12Yield of Diagnostic Tests and Management of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients: A Pilot StudyResults posted
- 2026-07-09Treatment of Bile Acid Diarrhoea With Atorvastatin (BASTA): A Randomised, Double-Blind, Placebo-Controlled, Crossover, Investigator-Initiated TrialResults expected Q4 2026
- 2026-03-18A Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT AloneResults expected Q2 2027
- 2026-04-01A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)Primary completion
- 2026-03-01Effect of Saccharomyces Boulardii CNCM I-745 on Antibiotic-perturbed Microbiota in Children: RESTORE STUDYPrimary completion
- 2026-01-26Effect of Saccharomyces Boulardii CNCM I-745 (Sb) on Bloody Diarrhea in Children. A Double Blind, Randomized, Controlled StudyPrimary completion
- 2026-01-01The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBSCompleted
- 2025-09-01A Randomized Controlled Trial Evaluating Single-dose Rifaximin Versus Azithromycin With Loperamide Adjunct for Treatment of Acute Watery DiarrheaPrimary completion
Industry & MarketView all 6Hide
- 2026-07-24A new, separate outbreak of the diarrhea-causing parasiteIndustry · STAT News
- 2026-07-21An experimental oral vaccine may prevent invasive bacterial diarrheaIndustry · Science News
- 2026-07-23U.S. health officials are investigating a new outbreak of a diarrhea-causing parasiteIndustry · STAT News
- 2026-07-17Lettuce at Taco Bell in five states confirmed as a source of diarrhea-causing parasiteIndustry · STAT News
- 2026-07-15What to know about the parasitic diarrhea outbreakIndustry · STAT News
- 2026-07-24IndustryA new, separate outbreak of the diarrhea-causing parasiteIndustry · STAT News
- 2026-07-23IndustryU.S. health officials are investigating a new outbreak of a diarrhea-causing parasiteIndustry · STAT News
- 2026-07-21IndustryAn experimental oral vaccine may prevent invasive bacterial diarrheaIndustry · Science News
- 2026-07-17IndustryLettuce at Taco Bell in five states confirmed as a source of diarrhea-causing parasiteIndustry · STAT News
- 2026-07-15IndustryWhat to know about the parasitic diarrhea outbreakIndustry · STAT News
- 2026-07-09IndustryOutbreak of diarrhea-causing parasite grows to more than 1,000 casesIndustry · STAT News
- 2026-07-09ClinicalTreatment of Bile Acid Diarrhoea With Atorvastatin (BASTA): A Randomised, Double-Blind, Placebo-Controlled, Crossover, Investigator-Initiated TrialResults expected Q4 2026
- 2026-04-29ClinicalBismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance GenesTerminated
- 2026-04-14ClinicalNext Generation ORS: Randomized Controlled Trial Comparing ORS With Calcium vs Standard ORS in Reducing Severity With Acute Watery Diarrhea in AdultsResults posted
- 2026-04-01ClinicalA Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)Primary completion
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Diarrhea3
- Gastrointestinal Microbiome3
- Clostridioides difficile2
- Disease Outbreaks2
- Global Health2
- Antibodies, Bispecific1
- Antineoplastic Agents1
- Antineoplastic Agents, Immunological1
Leading journals6
- The New England journal of medicine9
- Frontiers in cellular and infection microbiology3
- The Lancet. Infectious diseases2
- Annals of oncology : official journal of the European Society for Medical Oncology1
- BMC infectious diseases1
- BMC public health1
Leading researchers8
- Goto K2
- Guerrant RL2
- Kim DW2
- Loibl S2
- O'Reilly EM2
- Wolin EM2
- Abramson V1
- Ackland SP1
Affiliations (unnormalised)6
- Dana-Farber Cancer Institute2
- Mayo Clinic2
- National Cancer Center Hospital East2
- Princess Margaret Cancer Centre2
- Samsung Medical Center2
- University of California2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Diarrhea is a condition in which feces become more liquid or less consistent than normal, producing running stool. The MeSH definition emphasizes stool consistency rather than increased stool frequency or total fecal weight.
The supplied grounding supports infectious causes in the context of COVID-19 and antibiotic-associated diarrhea linked to disruption of the gut microbiota. It also supports diarrhea as a condition studied in relation to microbiome changes and probiotic use, but does not provide a broader causal list.
The grounding links diarrhea to alterations in the gastrointestinal microbiome, including reduced species diversity and altered metabolic activity after antibiotic exposure. It also suggests that probiotics may act by supporting challenged microbiota and directly influencing epithelial and immune cells, but it does not define a single unified mechanism for diarrhea itself.
Antibiotic exposure is supported as a risk factor for antibiotic-associated diarrhea through disruption of gut microbiota. COVID-19 is also associated with diarrhea in acute and long-COVID settings, but the grounding does not support additional general risk factors.
The supplied material supports probiotic-based approaches, including Saccharomyces boulardii, in some diarrhea-related contexts. It also supports management of diarrhea in COVID-19 and long COVID as part of broader multidisciplinary care, but does not provide a general standard treatment beyond these modality-level categories.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.